NYB.AI launches Vecura 2.0 for agentic molecular discovery

By AI, Created 3:16 PM UTC, May 29, 2026, /AGP/ – NYB.AI unveiled Vecura 2.0 on June 1, 2026, positioning the Singapore startup’s platform as an agentic AI system for molecular discovery and life science research. The launch leans on NVIDIA technologies to help research teams move from isolated model use to connected workflows for screening, docking, bioactivity prediction and decision support.

Why it matters: - Vecura 2.0 aims to reduce the friction that has kept many discovery teams from using frontier AI models at scale. - The platform is built to connect models, data, analysis tools and GPU computing in one workflow, which can cut manual coordination and infrastructure work. - NYB.AI is targeting pharmaceuticals, biotech, ingredient innovators and other research groups that need faster access to compute-intensive discovery tools.

What happened: - NYB.AI launched Vecura 2.0, an agentic AI platform for molecular discovery and life science research, on June 1, 2026. - The company is based in Singapore and develops infrastructure for molecular discovery and life science research. - Vecura 2.0 expands on Vecura 1.0 by adding an agentic layer that can reason across a research workflow. - The upgraded platform is designed to define scientific objectives, retrieve context, activate suitable models, compare outputs and generate structured decision support.

The details: - The original Vecura platform connected hundreds of AI models, scientific tools, biological data and molecular analysis capabilities. - Vecura 1.0 supported compound analysis, target exploration, formulation research, toxicity assessment and translational R&D. - Vecura 2.0 is intended to move from tool access to workflow execution. - The platform uses an agentic layer to understand research objectives, retrieve scientific context, select models, coordinate execution and produce next-step recommendations. - NYB.AI says the approach helps scientists focus on research direction instead of infrastructure management. - NYB.AI is developing a token-based access model for Vecura 2.0. - Through platform credits, users can access compound screening, bioactivity prediction and molecular docking. - The access model is aimed at biopharma companies, ingredient companies and research teams that do not want to build their own infrastructure.

Between the lines: - The launch reflects a broader push to turn AI in science from isolated model experiments into operational research infrastructure. - NVIDIA support gives NYB.AI both compute access and engineering guidance, which can matter as agentic workflows become more complex. - The emphasis on democratizing molecular discovery suggests NYB.AI is aiming beyond large pharmaceutical companies and specialized computational labs. - Vecura’s pitch is not just better models; it is orchestration, which is often the harder part of scientific AI adoption.

What’s next: - NYB.AI will showcase Vecura 2.0 at the NVIDIA Inception Startup Showcase during InnoVEX 2026 in Taipei from June 2–5, 2026. - The company expects the event to help validate Vecura 2.0 with enterprise leaders, investors, ecosystem partners and international buyers. - NYB.AI plans to demonstrate use cases across pharmaceuticals, nutraceuticals, cosmetics, food science, functional ingredients and consumer health. - The company is using the launch to expand visibility inside the NVIDIA Inception ecosystem and to position Vecura 2.0 as usable research infrastructure rather than a model demo.

The bottom line: - Vecura 2.0 is NYB.AI’s bet that the next breakthrough in scientific AI is not more models, but a system that can run discovery workflows end to end.